This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
April 6, 2005 — The U.S. Food and Drug Administration (FDA) announced in January revisions to safety labeling to advise healthcare professionals of the following changes: use of darbepoetin alfa ...
Anemia is a significant side effect of cancer and its therapies and occurs with treatment in 13% to 78% of patients with solid tumors and 30% to 40% of patients with lymphoma. In most cases, blood ...
LAS VEGAS—Switching anemic pre-dialysis chronic kidney disease (CKD) from darbepoetin to epoetin is associated with longer dosing intervals and lower drug costs, and hemoglobin levels are maintained ...
Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients Background: Anemia occurring in cancer patients undergoing Chemotherapy and or Radiotherapy causes ...
BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint. Vadadustat has met its primary and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback